Cargando…
Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
Large-cell neuroendocrine carcinoma (LCNEC) is a rare malignancy with poor prognosis. The rationale of the study was to determine the survival of LCNEC patients in I–IIIA clinical stages who underwent resection. A total of 53 LCNEC (89%) and combined LCNEC (11%) patients in stages I–IIIA who underwe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290504/ https://www.ncbi.nlm.nih.gov/pubmed/32392725 http://dx.doi.org/10.3390/jcm9051370 |
_version_ | 1783545692038365184 |
---|---|
author | Lowczak, Anna Kolasinska-Cwikla, Agnieszka Ćwikła, Jarosław B Osowiecka, Karolina Palucki, Jakub Rzepko, Robert Glinka, Lidka Doboszyńska, Anna |
author_facet | Lowczak, Anna Kolasinska-Cwikla, Agnieszka Ćwikła, Jarosław B Osowiecka, Karolina Palucki, Jakub Rzepko, Robert Glinka, Lidka Doboszyńska, Anna |
author_sort | Lowczak, Anna |
collection | PubMed |
description | Large-cell neuroendocrine carcinoma (LCNEC) is a rare malignancy with poor prognosis. The rationale of the study was to determine the survival of LCNEC patients in I–IIIA clinical stages who underwent resection. A total of 53 LCNEC (89%) and combined LCNEC (11%) patients in stages I–IIIA who underwent surgery with radical intent between 2002–2018 were included in the current study. Overall survival (OS) and time to recurrence (TTR) were estimated. Uni- and multivariable analyses were conducted using Cox-regression model. Patients were treated with surgery alone (51%), surgery with radiochemotherapy (4%), with radiotherapy (2%), with adjuvant chemotherapy (41%), or with neoadjuvant chemotherapy (2%). The median (95% Confidence Interval (CI)) OS and TTR was 52 months (20.1–102.1 months) and 20 months (7.0–75.6 months), respectively. Patients treated in clinical stage I showed better OS than patients in stages II–IIIA (p = 0.008). Patients with R0 resection margin (negative margin, no tumor at the margin) and without lymph node metastasis had significantly better TTR. In the multivariate analysis, age was an independent factor influencing OS. Recurrence within 1 year was noted in more than half cases of LCNEC. R0 resection margin and N0 status (no lymph node metastasis) were factors improving TTR. Age >64 years was observed as a main independent factor influencing OS. |
format | Online Article Text |
id | pubmed-7290504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72905042020-06-17 Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection Lowczak, Anna Kolasinska-Cwikla, Agnieszka Ćwikła, Jarosław B Osowiecka, Karolina Palucki, Jakub Rzepko, Robert Glinka, Lidka Doboszyńska, Anna J Clin Med Article Large-cell neuroendocrine carcinoma (LCNEC) is a rare malignancy with poor prognosis. The rationale of the study was to determine the survival of LCNEC patients in I–IIIA clinical stages who underwent resection. A total of 53 LCNEC (89%) and combined LCNEC (11%) patients in stages I–IIIA who underwent surgery with radical intent between 2002–2018 were included in the current study. Overall survival (OS) and time to recurrence (TTR) were estimated. Uni- and multivariable analyses were conducted using Cox-regression model. Patients were treated with surgery alone (51%), surgery with radiochemotherapy (4%), with radiotherapy (2%), with adjuvant chemotherapy (41%), or with neoadjuvant chemotherapy (2%). The median (95% Confidence Interval (CI)) OS and TTR was 52 months (20.1–102.1 months) and 20 months (7.0–75.6 months), respectively. Patients treated in clinical stage I showed better OS than patients in stages II–IIIA (p = 0.008). Patients with R0 resection margin (negative margin, no tumor at the margin) and without lymph node metastasis had significantly better TTR. In the multivariate analysis, age was an independent factor influencing OS. Recurrence within 1 year was noted in more than half cases of LCNEC. R0 resection margin and N0 status (no lymph node metastasis) were factors improving TTR. Age >64 years was observed as a main independent factor influencing OS. MDPI 2020-05-07 /pmc/articles/PMC7290504/ /pubmed/32392725 http://dx.doi.org/10.3390/jcm9051370 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lowczak, Anna Kolasinska-Cwikla, Agnieszka Ćwikła, Jarosław B Osowiecka, Karolina Palucki, Jakub Rzepko, Robert Glinka, Lidka Doboszyńska, Anna Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection |
title | Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection |
title_full | Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection |
title_fullStr | Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection |
title_full_unstemmed | Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection |
title_short | Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection |
title_sort | outcomes of patients with clinical stage i-iiia large-cell neuroendocrine lung cancer treated with resection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290504/ https://www.ncbi.nlm.nih.gov/pubmed/32392725 http://dx.doi.org/10.3390/jcm9051370 |
work_keys_str_mv | AT lowczakanna outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection AT kolasinskacwiklaagnieszka outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection AT cwikłajarosławb outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection AT osowieckakarolina outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection AT paluckijakub outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection AT rzepkorobert outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection AT glinkalidka outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection AT doboszynskaanna outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection |